Trial Profile
Clinical study of Apatinib Mesylate Tablets unite Docetaxel in the Second-line treatment of EGFR Wild-type Advanced Non-Squamous Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Sep 2018 Planned number of patients changed from 60 to 55.
- 03 Sep 2018 Planned End Date changed from 1 Jul 2017 to 31 Jul 2020.
- 07 Jul 2016 New trial record